CORCEPT THERAPEUTICS INC(CORT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,159 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CORT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CORCEPT THERAPEUTICS INC (CORT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CORT at 55.4/100 on a 32-signal composite quality model, placing it at rank #1,159 of 2,879 stocks — the top half of the AI-ranked universe. CORT scores in the top quartile across revenue growth (81.6). Areas of concern include earnings quality (10.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CORCEPT THERAPEUTICS INC reports quarterly revenue of $164.9M, net income of $-31.8M, free cash flow of $-17.0M. Top institutional holders of CORT by reported 13-F value include BlackRock,, RENAISSANCE TECHNOLOGIES, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CORT trades on the Nasdaq exchange and files with the SEC under CIK 1088856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CORT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CORCEPT THERAPEUTICS INC directly from SEC EDGAR. CORCEPT THERAPEUTICS INC's 13F Pro composite quality score has ranged between 8 and 82 since 2021, currently 55.4 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$164.9M
Net Income
Q1 2026
$-31.8M
Free Cash Flow
Q1 2026
$-17.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+39.9% YoYNet Income
+33.0% YoYOperating Income
+27.7% YoYEPS (Diluted)
+30.9% YoYTotal Assets
+35.2% YoYTotal Debt
Op. Cash Flow
+56.5% YoY| Metric | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $675.0M +39.9% | $482.4M +31.8% | $366.0M +3.4% | $353.9M +40.8% | $251.2M +57.8% | $159.2M |
| Net Income | $141.2M +33.0% | $106.1M -5.7% | $112.5M +6.1% | $106.0M +40.6% | $75.4M -41.6% | $129.1M |
| Operating Income | $137.0M +27.7% | $107.3M -13.8% | $124.5M -2.9% | $128.2M +43.2% | $89.5M +69.3% | $52.9M |
| EPS (Diluted) | $1.23 +30.9% | $0.94 +5.6% | $0.89 +4.7% | $0.85 +41.7% | $0.60 -42.3% | $1.04 |
| Total Assets | $840.6M +35.2% | $621.5M +46.7% | $423.8M -25.9% | $571.7M +83.4% | $311.7M +41.3% | $220.5M |
| Total Debt | — | — | — | — | — | $0.00 |
| Operating Cash Flow | $198.3M +56.5% | $126.7M -24.5% | $167.9M +10.5% | $152.0M +31.4% | $115.7M +89.8% | $60.9M |
AI Insight: CORT Financial Trends
Q1 2026 swings to a $32M net loss and negative $50M operating income — a sharp reversal that warrants close scrutiny of cost drivers.
• Revenue grew year-over-year from $164M in Q2 2024 to $208M in Q3 2025, but Q1 2026 at $165M shows no sequential or YoY progress.
• Operating income collapsed from $47M in Q3 2024 to negative $50M in Q1 2026, the first negative operating quarter in the dataset.
• Operating cash flow turned negative at -$17M in Q1 2026, reversing from positive $5M–$74M in prior quarters.
• No debt is reported across all eight quarters, leaving equity relatively stable around $632M–$648M through Q4 2025.
⚠ Q1 2026 operating loss of -$50M versus +$3M in Q1 2025 — a $53M swing in one year signals a major cost or one-time event to identify.
⚠ Equity declined from $683M in Q1 2025 to $638M in Q1 2026, first multi-quarter equity erosion trend in the dataset.
⚠ Debt remains unreported — confirm whether off-balance-sheet obligations or litigation accruals drove the Q1 2026 loss spike.
AI Insight: CORT Ratio Trends
Q1 2026 operating margin collapsed to -30.1%, the worst quarter in the visible dataset, signaling a severe one-quarter earnings shock.
• Operating margin fell from 25.5% in Q3 2024 to -30.1% in Q1 2026, a ~56pp deterioration over five quarters.
• Net profit margin turned deeply negative at -19.3% in Q1 2026, down from 18.1% in Q2 2025.
• ROIC swung from 29.2% in Q3 2024 to -31.1% in Q1 2026, erasing all capital efficiency gains.
• TTM operating margin of -1.1% and NPM of 6.2% reflect how deeply Q1 2026 dragged trailing results.
⚠ Q1 2026 losses are severe; confirm whether a litigation settlement, impairment, or one-off cost drove the -30.1% operating margin.
⚠ ROE turned negative at -19.9% in Q1 2026 after four consecutive positive quarters — watch for recovery in Q2 2026.
⚠ D/E data absent across all periods; leverage profile is unverifiable and warrants direct review of balance sheet disclosures.
Get alerted when CORT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CORCEPT THERAPEUTICS INC including:
Top Institutional Holders of CORT
BlackRock, Inc.
$489.8M12,151,276 shRENAISSANCE TECHNOLOGIES LLC
$229.1M5,682,783 shVANGUARD PORTFOLIO MANAGEMENT LLC
$194.3M4,820,568 shVANGUARD CAPITAL MANAGEMENT LLC
$164.4M4,077,196 shParallel Advisors, LLC
$160.3M3,977,404 shSTATE STREET CORP
$129.0M3,200,946 shFMR LLC
$128.6M3,190,192 shGEODE CAPITAL MANAGEMENT, LLC
$109.4M2,713,519 shFIRST TRUST ADVISORS LP
$87.6M2,173,376 shDIMENSIONAL FUND ADVISORS LP
$62.6M1,553,135 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $489.8M | 12,151,276 |
| RENAISSANCE TECHNOLOGIES LLC | $229.1M | 5,682,783 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $194.3M | 4,820,568 |
| VANGUARD CAPITAL MANAGEMENT LLC | $164.4M | 4,077,196 |
| Parallel Advisors, LLC | $160.3M | 3,977,404 |
| STATE STREET CORP | $129.0M | 3,200,946 |
| FMR LLC | $128.6M | 3,190,192 |
| GEODE CAPITAL MANAGEMENT, LLC | $109.4M | 2,713,519 |
| FIRST TRUST ADVISORS LP | $87.6M | 2,173,376 |
| DIMENSIONAL FUND ADVISORS LP | $62.6M | 1,553,135 |
More Healthcare Companies
View all Healthcare →Put CORT on your watchlist
Track score changes the day CORCEPT THERAPEUTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CORT a good stock to buy?
13F Pro's AI-powered analysis of CORCEPT THERAPEUTICS INC (CORT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CORT are available on the CORT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CORT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CORT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CORCEPT THERAPEUTICS INC's investment landscape.